ADC Therapeutics SA

ADCT

CH0499880968

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:21:38 2024-05-24 EDT			5-day change	1st Jan Change
3.675 ^USD	+0.96%		-10.37%	+121.39%

05-07	HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating	MT
05-06	Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday	MT

ADC Therapeutics SA Announces Resignation of Robert A. Schmidt as Company’S Chief Accounting Officer, Effective December 30, 2022

December 19, 2022 at 04:20 pm

ADC Therapeutics SA announced that, on December 15, 2022, Robert A. Schmidt informed the Company of his resignation as the Company's Chief Accounting Officer, effective December 30, 2022.

Latest news about ADC Therapeutics SA

HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating	05-07	MT
Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday	05-06	MT
ADC Therapeutics Launches $105 Million Offering; Shares Up 2% Pre-Bell	05-06	MT
Transcript : ADC Therapeutics SA, Q1 2024 Earnings Call, May 06, 2024	05-06
ADC Therapeutics SA's Cancer Drug Candidate Shows High Response Rate in Phase 2 Trial	05-06	MT
ADC Therapeutics SA Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma	05-06	CI
Transcript : ADC Therapeutics SA - Special Call	04-09
Sector Update: Health Care Stocks Slump Late Afternoon	04-04	MT
ADC Therapeutics Shares Rise After Completion of Dose Escalation Part of Phase 1b Lymphoma Trial	04-04	MT
Chiome Bioscience Cancels License Agreements with ADC Therapeutics	03-31	MT
Guggenheim Initiates ADC Therapeutics With Buy Rating, $11 Price Target	03-28	MT
Transcript : ADC Therapeutics SA, Q4 2023 Earnings Call, Mar 13, 2024	03-13
ADC Therapeutics SA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-13	CI
ADC Therapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
RBC Lifts Price Target on ADC Therapeutics to $8 From $6, 'Encouraged' by Competitive Positioning; Outperform, Speculative Risk Kept	02-26	MT
HC Wainwright Raises Price Target on ADC Therapeutics to $9 From $3, Maintains Buy Rating	02-20	MT
Certain Common Shares of ADC Therapeutics SA are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	02-02	CI
Certain Restricted Stock Units of ADC Therapeutics SA are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	02-02	CI
Certain Warrants of ADC Therapeutics SA are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	02-02	CI
Certain Options of ADC Therapeutics SA are subject to a Lock-Up Agreement Ending on 3-FEB-2024.	02-02	CI
ADC Therapeutics SA Enters First Amendment to the Loan Agreement	01-19	CI
ADC Therapeutics Regains Compliance With NYSE Continued Listing Standards	01-04	MT
HC Wainwright Adjusts Price Target on ADC Therapeutics to $3 From $12, Keeps Buy Rating	11-20	MT
TD Cowen Downgrades ADC Therapeutics to Market Perform From Outperform	11-09	MT

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkinâs lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Sector

Biotechnology & Medical Research

Calendar

2024-06-13 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for ADC Therapeutics SA

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.64 USD

Average target price

10 USD

Spread / Average Target

+174.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADC THERAPEUTICS SA	+121.39%	350M
VERTEX PHARMACEUTICALS INCORPORATED	+11.93%	116B
REGENERON PHARMACEUTICALS, INC.	+13.01%	106B
BIONTECH SE	-9.17%	23.89B
ARGENX SE	-1.69%	21.58B
GENMAB A/S	-10.60%	18.96B
WUXI APPTEC CO., LTD.	-41.25%	16.96B
BEIGENE, LTD.	-14.49%	16.33B
NEUROCRINE BIOSCIENCES, INC.	+6.70%	14.14B
SAREPTA THERAPEUTICS, INC.	+31.07%	12.02B

Bio Therapeutic Drugs